Psoriasis Treatment Market Research Report - Global Forecast till 2025

Global Psoriasis Treatment Market Research Report: Information by Drug Class [Tumour Necrosis Factor Inhibitors (Adalimumab, Infliximab and Etanercept), Interleukin-Inhibitors (Ustekinumab, Secukinumab, Ixekizumab and Brodalumab), Vitamin D Analogues (Calcitriol, Calcipotriol and Tacalcitol)], Treatment Type {Topicals [Over-the-counter (OTC) Topicals, Topical Non-Steroids and Topical Steroids], Systemic (Retinoid, Cyclosporine and Methotrexate), Biologics [Tumour Necrosis Factor Alpha (TNF-α) Inhibitors, Interleukin in 12 and 23 (IL-12/23) Inhibitors, Interleukin in 17 (IL-17) Inhibitor, T cell Inhibitor]} and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025

Market Scenario

Psoriasis Treatment Market is expected to register 7.3% CAGR during the forecast period of 2019 to 2025 and is expected to reach USD 13.1 Billion in 2025.

Psoriasis is a chronic inflammatory skin condition that is often connected with systemic manifestations. The market for psoriasis treatment is expected to grow at a moderate pace.

The major factors influencing the growth of the market include the increasing research and development for the treatment of psoriasis, increasing awareness for the treatment, and development of advanced technology. Furthermore, increasing prevalence of psoriasis is a major factor for influencing the growth of the market. It is found that the incidence of psoriasis ranges between 0.09% and 11.4% in various countries, making it a serious problem across the globe. It is also found that it commonly occurs in the age group of 50 to 69. According to studies, it is found that individual suffering from psoriasis may further develop other serious diseases, including cardiovascular and other noncommunicable diseases.

Segmentation

The Global Psoriasis Treatment Market is segmented based on drug class, treatment type, and region.

The global market for psoriasis treatment, by drug class, is segmented into tumour necrosis factor inhibitors, Interleukin-inhibitors, and vitamin D analogues. Moreover, tumour necrosis factor inhibitors are segmented into adalimumab, infliximab, and etanercept. Furthermore, Interleukin-inhibitors is segmented into ustekinumab, Secukinumab, Ixekizumab, and brodalumab. Vitamin D analogues are segmented into calcitriol, calcipotriol, and tacalcitol.

Based on treatment, the global market is segmented into topicals, systemic, and biologics. Topicals are further sub-segmented into over the counter (OTC) topicals, topical non-steroids, topical steroids. Systemic is segmented into retinoid, cyclosporine, and methotrexate. Biologics is sub-segmented into tumour necrosis factor-alpha (TNF-α) inhibitors, Interleukin in 12 and 23 (IL-12/23) inhibitors, Interleukin in 17 (IL-17) inhibitor, and T cell inhibitor.

In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The psoriasis treatment market in the Americas has been segmented into North America and South...
America, with the North American market divided into the US and Canada. The European psoriasis treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The psoriasis treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The psoriasis treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key Players
Some of the Key Players operating in the Global Psoriasis Treatment Market are Novartis International AG (Switzerland), UCB (Belgium), AstraZeneca (UK), Celgene Corporation (US), Johnson & Johnson (US), Pfizer Inc (US), Merck and Co. Inc (US), AbbVie (US), Amgen (US), and Eli Lilly and Company (US).

Regional Market Summary

Global Psoriasis Treatment Market Share (%), by Region, 2018

Sources: MRFR Analysis

The Americas dominated the psoriasis treatment market owing to the increasing awareness among the people, the presence of major manufacturers, and increasing prevalence of psoriasis. According to a recent study, it was found that more than 8 million Americans have psoriasis, also in the US more than 150,000 new cases of psoriasis are detected every year.

In 2018, Europe accounted for the second-largest market share. However, Asia-Pacific is expected to grow with the fastest growth rate throughout the forecast period due to rising participation of market players and the growing geriatric population. On the other hand, the Middle East & Africa is expected to hold the least share of the psoriasis treatment market due to the low economic development, especially in Africa.

Global Psoriasis Treatment Market, by Drug Class

- Tumour Necrosis Factor Inhibitors
  - Adalimumab
  - Infliximab
  - Etanercept
- K.in-Inhibitors
  - Ustekinumab
  - K.inumab
  - Ixekizumab
  - Brodalumab
- Vitamin D Analogues
  - Calcitriol
  - Calcioptriol
  - Tacalcitol

Global Psoriasis Treatment Market, by Treatment Type
Topicals
- Over the Counter (OTC)
- Topical Non-Steroids
- Topical Steroids

Systemic
- Retinoid
- Cyclosporine
- Methotrexate

Biologics
- Tumour Necrosis Factor Alpha (TNF-a) Inhibitors
- K.in 12 and 23 (IL-12/23) Inhibitors
- K.in 17 (IL-17) Inhibitor
- T Cell Inhibitor

Global Psoriasis Treatment Market, by Region

Americas
- North America
  - US
  - Canada
- Latin America

Europe
- Western Europe
  - Germany
  - France
  - Italy
  - Spain
  - UK
  - Rest of Western Europe
- Eastern Europe

Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific

Middle East & Africa
- Middle East
- Africa

Intended Audience
- Pharmaceutical companies
- Government research institutes
- Academic institutes and universities
- Venture capitalists

Contents:

1. REPORT PROLOGUE
2. MARKET INTRODUCTION
   2.1. Definition
2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL PSORIASIS TREATMENT MARKET, BY DRUG CLASS

6.1. Overview

6.2. Tumour Necrosis Factor Inhibitors

Market Estimates & Forecast, by Region, 2019–2025

6.2.1. Adalimumab

Market Estimates & Forecast, by Region, 2019–2025

6.2.2. Infliximab

Market Estimates & Forecast, by Region, 2019–2025

6.2.3. Etanercept

Market Estimates & Forecast, by Region, 2019–2025

6.3. Anticholinergics

Market Estimates & Forecast, by Region, 2019–2025
6.3.1. Ustekinumab
Market Estimates & Forecast, by Region, 2019–2025

6.3.2. Secukinumab
Market Estimates & Forecast, by Region, 2019–2025

6.3.3. Ixekizumab
Market Estimates & Forecast, by Region, 2019–2025

6.3.4. Brodalumab
Market Estimates & Forecast, by Region, 2019–2025

6.4. Vitamin D Analogues
Market Estimates & Forecast, by Region, 2019–2025

6.4.1. Calcitriol
Market Estimates & Forecast, by Region, 2019–2025

6.4.2. Calcipotriol
Market Estimates & Forecast, by Region, 2019–2025

6.4.3. Tacalcitol
Market Estimates & Forecast, by Region, 2019–2025

7. GLOBAL PSORIASIS TREATMENT MARKET, BY TREATMENT TYPE

7.1. Overview

7.2. Topicals
Market Estimates & Forecast, by Region, 2019–2025

7.2.1. Over-The-Counter (OTC) Topicals
Market Estimates & Forecast, by Region, 2019–2025

7.2.2. Topical Non-Steroids
Market Estimates & Forecast, by Region, 2019–2025

7.2.3. Topical Steroids
Market Estimates & Forecast, by Region, 2019–2025
7.3. Systemic
Market Estimates & Forecast, by Region, 2019–2025

7.3.1. Retinoid
Market Estimates & Forecast, by Region, 2019–2025

7.3.2. Cyclosporine
Market Estimates & Forecast, by Region, 2019–2025

7.3.3. Methotrexate
Market Estimates & Forecast, by Region, 2019–2025

7.4. Biologics
Market Estimates & Forecast, by Region, 2019–2025

7.4.1. Tumour Necrosis Factor Alpha (TNF-α) Inhibitors
Market Estimates & Forecast, by Region, 2019–2025

7.4.2. Interleukin 12 and 23 (IL-12/23) Inhibitors
Market Estimates & Forecast, by Region, 2019–2025

7.4.3. Interleukin 17 (IL-17) Inhibitor
Market Estimates & Forecast, by Region, 2019–2025

7.4.4. T Cell Inhibitor
Market Estimates & Forecast, by Region, 2019–2025

8. GLOBAL PSORIASIS TREATMENT MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. North America
8.2.1.1. US
8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe
8.3.1.1. Germany
8.3.1.2. France
8.3.1.3. Italy
8.3.1.4. Spain
8.3.1.5. UK
8.3.1.6. Rest of Western Europe
8.3.2. Eastern Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle East & Africa
8.5.1. Middle East
8.5.2. Africa

9. COMPANY LANDSCAPE

9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global Psoriasis Treatment Market
9.5. Competitive Benchmarking
9.6. Leading Players in Terms of Number of Developments in the Global Psoriasis Treatment Market
9.7. Key Developments and Growth Strategies
9.7.1. New Application Launch/Service Deployment
9.7.2. Mergers and Acquisitions
9.7.3. Joint Ventures
9.8.1. Sales & Operating Income 2018
9.8.2. Major Players R&D Expenditure 2018
9.9. Major Players Capital Market Ratio

10. COMPANY PROFILES

10.1. Novartis International AG
10.1.1. Company Overview
10.1.2. Application Type Overview
10.1.3. Financial Overview
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. UCB
10.2.1. Company Overview
10.2.2. Application Type Overview
10.2.3. Financial Overview
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies

10.3. AstraZeneca
10.3.1. Company Overview
10.3.2. Application Type Overview
10.3.3. Financial Overview
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies

10.4. Celgene Corporation.
10.4.1. Company Overview
10.4.2. Application Type Overview
10.4.3. Financial Overview
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies

10.5. Johnson & Johnson
10.5.1. Company Overview
10.5.2. Application Type Overview
10.5.3. Financial Overview
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies

10.6. Pfizer Inc
10.6.1. Company Overview
10.6.2. Application Type Overview
10.6.3. Financial Overview
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies

10.7. Merck and Co. Inc
10.7.1. Company Overview
10.7.2. Application Type Overview
10.7.3. Financial Overview
FIGURE 23   AMGEN

FIGURE 24   ELI LILLY AND COMPANY